爱学习的瑞瑞子
Lv6
2529 积分
2022-09-03 加入
-
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
5天前
已完结
-
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
5天前
已完结
-
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
5天前
已完结
-
Top advances of the year: Perioperative therapy for lung cancer
8天前
已完结
-
A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer
13天前
已完结
-
Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer
16天前
已完结
-
The role of ctDNA in endometrial cancer: A tool for risk stratification and disease monitoring
16天前
已完结
-
The implications of IDH mutations for cancer development and therapy
19天前
已完结
-
Fibroblast growth factor signalling: from development to cancer
21天前
已完结
-
非小细胞肺癌围手术期免疫规范化治疗专家共识
21天前
已完结